Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Briquilimab/Low-Dose TBI/Fludarabine Shows Promise in MDS/AML Undergoing AlloHCTFebruary 23rd 2023
In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.
Pano/GemBuMel May Be Safe/Effective for Treatment of High-Risk, R/R MyelomaFebruary 22nd 2023
In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.
Sorafenib Plus SBRT Shows Improvement in QOL Measure for HCCFebruary 13th 2023
Laura A. Dawson, MD, FRCPC, discusses quality-of-life outcomes from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib versus sorafenib alone in hepatocellular carcinoma.
Frontline Liposomal Irinotecan/NALIRIFOX Improves Survival in mPDACFebruary 10th 2023
In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.
Claudin 18.2 Represents New Druggable Target for CLDN18.2+/HER2-, Advanced/Metastatic Gastric and GEJ AdenocarcinomaFebruary 8th 2023
In an interview with Targeted Oncology, Samuel Klempner, MD, discussed the significance of the phase 3 SPOTLIGHT study and the future impact of claudin 18.2 as a biomarker to treat cancers of the stomach and esophagus.
Primary Analysis of Phase 3 TRANSFORM Study Confirms Benefit of Liso-Cel in LBCLFebruary 7th 2023
In an interview with Targeted Oncology, Jeremy Abramson, MD, discussed findings of the phase 3 TRANSFORM study which were presented at the 2022 American Society of Hematology Annual Meeting.
Beckermann on Recent Data and Hopes for the Evolving RCC LandscapeFebruary 2nd 2023
In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.
SBRT Plus Sorafenib Improves Survival in Locally Advanced HCCFebruary 1st 2023
In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.
Botensilimab/Balstilimab Combo Shows Potential for MSS CRCJanuary 31st 2023
In an interview with Targeted Oncology, Benjamin Schlechter, MD, FACS, discussed the background of a phase 1a/1b trial in microsatellite stable colorectal cancer and how these findings will influence future research.
Survival Outcomes for Metastatic RCC and Sarcomatoid DedifferentiationJanuary 31st 2023
Matthew T. Campbell, MD, discusses survival outcomes for patients with both metastatic renal cell carcinoma and sarcomatoid dedifferentiation and how they each have evolved over the past few years.